MGTA Magenta Therapeutics Inc.

15.01
-0.2  -1%
Previous Close 15.21
Open 15.22
Price To Book 3.45
Market Cap 502332555
Shares 33,466,526
Volume 53,962
Short Ratio
Av. Daily Volume 187,741

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Will evaluate development as less toxic conditioning becomes available.
MGTA-456
Sickle cell disease
Phase 2 data noted all patients met primary endpoint.
MGTA-456
Inherited Metabolic Disorders (IMD)
Phase 2 data due at ASH 2019.
MGTA-456
Acute Lymphoblastic Leukemia
Phase 1 initial data due at ASH 2019.
MGTA-145
Healthy volunteers

Latest News

  1. 3 Stocks That Have More Than Tripled So Far in 2019
  2. Raymond James Thinks Magenta Still Has Upside
  3. Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
  4. How Many Insiders Bought Magenta Therapeutics, Inc. (NASDAQ:MGTA) Shares?
  5. Magenta Therapeutics to Present at Investor Conferences in March
  6. Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate
  7. Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting
  8. Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant
  9. Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference
  10. Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019
  11. Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit
  12. Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders
  13. Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate
  14. Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH
  15. Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer
  16. Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results
  17. Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expansion Programs
  18. Magenta Therapeutics Added to Russell 2000 and 3000 Indexes
  19. Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results
  20. Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference